https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-932023-01-09 00:00:002023-01-09 00:00:00Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-04 / Int J Mol Sci 2023 Jan;24(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-04 / Int J Mol Sci 2023 Jan;24(2)2023-01-04 00:00:002023-01-04 00:00:00Neutrophils in Dendritic Cell-Based Cancer Vaccination: The Potential Roles of Neutrophil Extracellular Trap Formation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-121
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-1212023-01-01 00:00:002023-05-30 16:23:26Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-23 / Neuro Oncol 2022 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-23 / Neuro Oncol 2022 Dec;2022-12-23 00:00:002022-12-23 00:00:00Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-12 / Front Immunol 2022;13:1080947
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-12 / Front Immunol 2022;13:10809472022-12-12 00:00:002022-12-12 00:00:00Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-04 / Cancer Med 2023 Mar;12(6):7207-7221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-04 / Cancer Med 2023 Mar;12(6):7207-72212022-12-04 00:00:002023-05-30 16:29:12Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-01 / Transl Pediatr 2022 Dec;11(12):2040-2056
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-01 / Transl Pediatr 2022 Dec;11(12):2040-20562022-12-01 00:00:002024-01-30 11:22:05Immunotherapy for the treatment of pediatric brain tumors: a narrative review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-11-26 / J Clin Med 2022 Nov;11(23)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-11-26 / J Clin Med 2022 Nov;11(23)2022-11-26 00:00:002023-01-31 13:00:05Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-10-27 / Int J Mol Sci 2022 Oct;23(21)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-10-27 / Int J Mol Sci 2022 Oct;23(21)2022-10-27 00:00:002023-01-31 13:01:45Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-10-14 / Clin Exp Med 2022 Nov;22(4):667-672
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-10-14 / Clin Exp Med 2022 Nov;22(4):667-6722022-10-14 00:00:002022-10-14 00:00:00Commentary on „Systematic review about complementary medical hyperthermia in oncology“ by Liebl et al
